Equities research analysts expect that Natera, Inc. (NASDAQ:NTRA) will report ($1.05) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Natera’s earnings, with estimates ranging from ($1.13) to ($0.98). Natera reported earnings of ($0.45) per share in the same quarter last year, which indicates a negative year over year growth rate of 133.3%. The business is expected to report its next earnings report on Wednesday, May 5th.
According to Zacks, analysts expect that Natera will report full year earnings of ($4.24) per share for the current financial year, with EPS estimates ranging from ($4.39) to ($4.10). For the next year, analysts forecast that the business will report earnings of ($3.24) per share, with EPS estimates ranging from ($3.89) to ($2.40). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Natera.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 25th. The medical research company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.28). Natera had a negative net margin of 52.11% and a negative return on equity of 53.39%.
NTRA has been the subject of several research analyst reports. Canaccord Genuity lifted their price target on shares of Natera from $112.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, January 14th. Truist began coverage on shares of Natera in a research report on Wednesday, January 27th. They set a “buy” rating and a $143.00 target price for the company. SVB Leerink boosted their target price on shares of Natera from $95.00 to $140.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 20th. Craig Hallum boosted their target price on shares of Natera from $92.00 to $118.00 and gave the stock a “buy” rating in a research report on Monday, January 4th. Finally, Piper Sandler boosted their target price on shares of Natera from $127.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, March 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $102.33.
NTRA opened at $101.42 on Monday. Natera has a 1-year low of $28.30 and a 1-year high of $127.19. The company has a current ratio of 4.68, a quick ratio of 4.57 and a debt-to-equity ratio of 0.37. The company has a market cap of $8.78 billion, a P/E ratio of -42.61 and a beta of 1.66. The company has a fifty day moving average price of $105.72 and a two-hundred day moving average price of $95.29.
In related news, CEO Steven Leonard Chapman sold 1,558 shares of the business’s stock in a transaction dated Monday, April 5th. The shares were sold at an average price of $104.09, for a total transaction of $162,172.22. Following the transaction, the chief executive officer now directly owns 46,037 shares in the company, valued at $4,791,991.33. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 1,899 shares of the business’s stock in a transaction dated Thursday, February 25th. The stock was sold at an average price of $106.73, for a total transaction of $202,680.27. Following the transaction, the chief financial officer now owns 57,936 shares in the company, valued at $6,183,509.28. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 151,164 shares of company stock worth $15,039,386. 9.29% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Capstone Triton Financial Group LLC purchased a new position in Natera in the fourth quarter valued at about $37,000. Harvest Fund Management Co. Ltd purchased a new position in Natera in the fourth quarter valued at about $39,000. James Investment Research Inc. purchased a new position in Natera in the fourth quarter valued at about $50,000. Heritage Wealth Advisors boosted its stake in Natera by 18.8% in the fourth quarter. Heritage Wealth Advisors now owns 855 shares of the medical research company’s stock valued at $85,000 after acquiring an additional 135 shares during the last quarter. Finally, Sittner & Nelson LLC purchased a new position in Natera in the fourth quarter valued at about $100,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Can systematic risk be avoided?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.